Browsing by Author "Ebasone, Peter V."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.
    (2025-May-20) Loosli, Tom; Bolton-Moore, Carolyn; Buzaalirwa, Lydia; Byakwaga, Helen; Çelikağ, İpek; Chimbetete, Cleophas; Ebasone, Peter V.; Giandhari, Jennifer; Han, Nuri; Huwa, Jacqueline; Kasozi, Charles; Mafoua, Adolphe; Messou, Eugène ; Minga, Albert; Muula, Guy; Muyindike, Winnie; Ndala, Arcel C. M.; Sauermann, Mamatha ; Semeere, Aggrey; Singh, Lavanya; Kouyos, Roger D.; Lessells, Richard; Egger, Matthias
    Dolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.
  • Thumbnail Image
    Item
    Global Trends in CD4 Measurement and Immunosuppression at ART Initiation Among Children With HIV.
    (2025-Apr-04) Patten, Gabriela; Malateste, Karen; Bolton-Moore, Carolyn; Sipambo, Nosisa; Mokone, Limpho; Anderegg, Nanina; Wools-Kaloustian, Kara; Michael, Denna; Odhiambo, Francesca ; Kasozi, Charles; Desmonde, Sophie; Amorissani-Folquet, Madeleine; Leroy, Valériane; Kumara, Dewi W.; Nallusamy, Revathy; Kinikar, Aarti; Quy, Du T.; Yotebieng, Marcel; Ebasone, Peter V.; Lelo, Patricia; Pinto, Jorge; Rouzier, Vanessa; Machado, Daisy M.; Haw, Nel J.; Ford, Nathan
    Eligibility for antiretroviral therapy is no longer based on immune criteria. In a global cohort of 97,453 children, between 2005 and 2021, we observed large declines in CD4 measurement, from 51% to 12% among <5 seconds, and from 74% to 20% among those 5-14 years of age. Lack of CD4 testing may negatively affect clinical care and surveillance of severe immune suppression.